drug
dolutegravir sodium
Marketedupdated 5mo agoby ViiV Healthcare Company
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval170 co-mentions · 56 sources
- drugdolutegravir sodium ODT99 co-mentions · 58 sources
- tagSmall Molecule85 co-mentions · 56 sources
- drug(dolutegravir sodium + lamivudine)16 co-mentions · 16 sources
- drug(dolutegravir sodium + rilpivirine hydrochloride)11 co-mentions · 11 sources
- company$GSKGSK plc2 co-mentions · 2 sources
- company$GLAXFGSK plc2 co-mentions · 2 sources
- tagInfectious Disease2 co-mentions · 2 sources
all catalysts(1)
Trials studying dolutegravir sodium
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 5, 2027
363 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (16)
- Jun 8, 2030patentUS 9242986*PED3.7y
- Jun 8, 2030patentUS 9242986*PED3.7y
- Jun 8, 2030patentUS 9242986*PED3.7y
- Jun 8, 2030patentUS 9242986*PED3.7y
- Dec 8, 2029compositionUS 92429863.2y
- Dec 8, 2029compositionUS 92429863.2y
- Dec 8, 2029compositionUS 92429863.2y
- Dec 8, 2029compositionUS 92429863.2y
- Apr 5, 2028patentUS 8129385*PED1.5y
- Apr 5, 2028patentUS 8129385*PED1.5y
- Apr 5, 2028patentUS 8129385*PED1.5y
- Apr 5, 2028patentUS 8129385*PED1.5y
- Oct 5, 2027compositionUS 8129385363d
- Oct 5, 2027compositionUS 8129385363d
- Oct 5, 2027compositionUS 8129385363d
- Oct 5, 2027compositionUS 8129385363d
News(1)
- GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyardGSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any…fiercebiotech · 2mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that